Novelos Therapeutics

Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based

Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The Company's compound, NOV-002 is a small-molecule compound based on a formulation of oxidized glutathione that has been administered to approximately 1,000 cancer patients in clinical trials. As of December 31, 2009, NOV-002 was in Phase II development for solid tumors in combination with chemotherapy. The Company's second glutathione-based compound, NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties.